<DOC>
	<DOC>NCT01169792</DOC>
	<brief_summary>The genetic polymorphisms of the cytochrome P450 may influence on the metabolism of tamoxifen. The investigators want to - evaluate the frequency or incidence of the genetic polymorphisms of cytochrome P450 subfamilies(CYP2D6, CYP3A4/5 and CYP2C19) in breast cancer patients, and - analyze the association between the genetic polymorphisms of cytochrome P450 subfamilies and clinical outcomes in breast cancer patients treated by adjuvant tamoxifen therapy.</brief_summary>
	<brief_title>Study of Cytochrome P450 Polymorphisms (CYP2D6, CYP3A4/5 and CYP2C19) in Breast Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<mesh_term>Antineoplastic Agents, Hormonal</mesh_term>
	<criteria>age â‰¥ 18 years Breast cancer patients who underwent surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>Tamoxifen</keyword>
	<keyword>Cytochrome P-450 CYP2D6</keyword>
	<keyword>Polymorphism</keyword>
	<keyword>Single nucleotide</keyword>
	<keyword>Antineoplastic Agents, Hormonal</keyword>
</DOC>